Ratio Therapeutics and PharmaLogic expand manufacturing collaboration to support clinical development of [Ac-225]RTX-2358

CAR-T Digest - August 2020

Weekly Digest - June 2026

29 May 2026: Ratio Therapeutics and PharmaLogic expand manufacturing collaboration to support clinical development of [Ac-225]RTX-2358

Ratio Therapeutics and PharmaLogic have expanded their manufacturing collaboration to support the clinical development of [Ac-225]RTX-2358, Ratio’s lead fibroblast activation protein-alpha (FAP)-targeted radiotherapeutic candidate, reinforcing the companies’ commitment to advancing next-generation targeted radiopharmaceuticals for cancer treatment
Building on the ongoing phase 1/2 ATLAS study, the collaboration adds manufacturing capacity through PharmaLogic’s Idaho Falls facility while introducing production process enhancements designed to enable larger-scale multi-dose batch manufacturing, addressing a key bottleneck often faced by radiopharmaceutical developers
As [Ac-225]RTX-2358 advances in relapsed or refractory soft tissue sarcoma, the strengthened manufacturing network reduces execution risk for future registrational studies while positioning Ratio to rapidly scale production if clinical data continue to validate the therapeutic potential of FAP-targeted alpha therapy
The move is particularly significant because Actinium-225-based therapies require highly specialized, reliable, and redundant manufacturing capabilities, making supply chain readiness a critical competitive advantage rather than simply an operational consideration
More broadly, this development reflects a growing trend across the radiopharmaceutical sector where manufacturing readiness is becoming a key value driver, with companies increasingly investing in scalable supply infrastructure early to avoid delays between clinical success and commercial launch